Archive for October, 2008

Galantamine switching previous therapies for Alzheimer’s disease to galantamine

Galantamine Determining the optimal conditions for switching patients from donepezil to galantamine

Galantamine rationale for switching from donepezil to galantamine

Galantamine facilitates synaptic transmission in the central nervous system

Galantamine an allosterically potentiating ligand

Galantamine nicotinic receptors in Alzheimer’s

Galantamine effect on nicotinic receptor binding

Galantamine nicotinic modulation in older rabbits

Galantamine sensitizes nicotinic receptors

Galantamine nicotinic receptors, galantamine and Alzheimer’s

Galantamine acetylcholinesterase inhibition

Galantamine switching cholinesterase inhibitors in patients with Alzheimer’s

Galantamine safety and tolerability in Japanese and Caucasians

Galantamine efficacy in patients previously treated with AChEIs

Galantamine effect on memory & nicotinic receptors

Galantamine maintaining cognitive function in Alzheimer disease

Galantamine therapeutic effects beyond cognition

Galantamine efficacy of galantamine in dementia and Alzheimer’s disease

Galantamine for Alzheimer’s disease

Galantamine new developments in the treatment of Alzheimer’s disease

Galantamine novel approach to the treatment of Alzheimer disease

Galantamine a new Alzheimer drug with a past life

Galantamine maintaining functional abilities in Alzheimer disease

Galantamine its use in Alzheimer’s

Galantamine a new treatment for Alzheimer’s

« Previous Entries